LOS ANGELES, CA / ACCESSWIRE / July 30, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, Inc. (“Surface” or “the Company”) (NASDAQ: SURF) for false and misleading SEC filings.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
Cell: 424-303-1964
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 554067

LOS ANGELES, CA / ACCESSWIRE / July 30, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Capital One Finance Corporation (“Capital One” or “the Company”) (NYSE: COF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Capital One admitted on July 29, 2019, that it suffered a massive data breach exposing the personal data of more than 100 million customers and card applicants. The hacker who accessed the information posted it to a publicly available GitHub account, further exposing sensitive details about Capital One customers and applicants to access by anyone on the Internet. Based on this news, shares of Capital One fell almost 6% on July 30.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 554066

NEW YORK, NY / ACCESSWIRE / July 30, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Pivotal Software, Inc. (NYSE:PVTL)

Investors Affected : investors who purchased common stock pursuant or traceable to the April 2018 initial public offering and/or Pivotal securities between April 24, 2018 and June 4, 2019.

A class action has commenced on behalf of certain shareholders in Pivotal Software, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Pivotal was facing major problems with its sales execution and a complex technology landscape; (ii) the foregoing headwinds resulted in deferred sales, lengthening sales cycles, and diminished growth as its customers and the industry’s sentiment shifted away from Pivotal’s principal products because the Company’s products were outdated, inadequate, and incompatible with the industry-standard platform; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/pivotal-software-inc-loss-submission-form/?id=2686&from=1

Cloudera, Inc. (NYSE:CLDR)

Investors Affected: April 28, 2017 – June 5, 2019

A class action has commenced on behalf of certain shareholders in Cloudera, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Cloudera was finding it increasingly difficult to identify large enterprises interested in adopting the Company’s Hadoop-based platform; (ii) Cloudera needed to expend an increasing amount of capital on sales and marketing activities to generate new revenues, even as new revenue opportunities were diminishing; and (iii) Cloudera had materially diminished sales opportunities and prospects and could not generate annual positive cash flows.

Shareholders may find more information at https://securitiesclasslaw.com/securities/cloudera-inc-loss-submission-form/?id=2686&from=1

Eros International Plc (NYSE:EROS)

Investors Affected: July 28, 2017 – June 5, 2019

A class action has commenced on behalf of certain shareholders in Eros International Plc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Eros and its executives engaged in a scheme to use related-party transactions to fabricate receivables that they reported in Eros’s public financial disclosures; (2) because of this scheme, Eros’s financial position was weaker than what the Company disclosed; (3) consequently, the Company’s Indian subsidiary, Eros International Media Ltd (“EIML”), missed loan payments and had its credit downgraded; and (4) due to the foregoing, Defendants’ statements about Eros’s receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/eros-international-plc-loss-submission-form/?id=2686&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 554060

SAN FRANCISCO, CA / ACCESSWIRE / July 30, 2019 / Hagens Berman Sobol Shapiro LLP alerts investors in Karyopharm Therapeutics Inc.’s (NASDAQ: KPTI) April 28, 2017 and May 7, 2018 public offerings to the firm’s ongoing investigation into possible securities law violations.

If you purchased Karyopharm Therapeutics common stock in the Company’s April 28, 2017 or the May 7, 2018 follow-on offerings, and suffered losses contact Hagens Berman.

https://www.hbsslaw.com/investor-fraud/KPTI

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing

KPTI@hbsslaw.com.

The investigation focuses on whether the Company’s registration statements for the 2017 and 2018 follow-on offerings misled investors about the safety and efficacy of selinexor, a drug intended for the treatment of various types of cancer that Karyopharm was developing. More specifically, Karyopharm’s offering documents claimed that selinexor studies showed the drug was “well-tolerated” by patients and explained there were “no new clinically significant adverse events in the patients receiving selinexor.”

However, on February 22, 2019, the FDA disclosed that (i) a previously cancelled selinexor trial resulted in “worse overall survival” for certain patients, and (ii) “[t]reatment with selinexor is associated with significant toxicity” and has “limited efficacy.”

“We’re focused on investors’ losses and the extent to which Defendants’ statements about selinexor’s safety and efficacy may have misled investors,” said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Karyopharm should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email KPTI@hbsslaw.com.

# # #

About Hagens Berman

Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein
510-725-3000

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 554054

SAN FRANCISCO, CA / ACCESSWIRE / July 30, 2019 / Hagens Berman Sobol Shapiro LLP reminds investors in CareDx, Inc. (NASDAQ: CDNA) of the firm’s ongoing investigation of possible disclosure violations.

The investigation concerns matters raised on July 16, 2019 by Kerrisdale Capital’s report questioning the efficacy and safety of CareDx’s AlloSure diagnostic test.

More specifically, the report accuses AlloSure of being ineffective in diagnosing kidney rejection and dangerous if used as directed by the Company. According to the report “[e]very single clinical paper and study of AlloSure leads, in our view, to one inescapable conclusion: AlloSure is an utter failure as a comprehensive biomarker of rejection.”

If you purchased or otherwise acquired CareDx securities before July 16, 2019 and suffered losses or have information that may assist this investigation, contact Hagens Berman:

https://www.hbsslaw.com/investor-fraud/caredx

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing

CDNA@hbsslaw.com.

“We’re focused on investors’ losses and whether the Company may have misled investors about the effectiveness of AlloSure,” said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding CareDx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email CDNA@hbsslaw.com.

# # #

About Hagens Berman

Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein
510-725-3000

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 554053

SAN FRANCISCO, CA / ACCESSWIRE / July 30, 2019 / Hagens Berman Sobol Shapiro LLP reminds investors in Cloudera Inc. (NYSE: CLDR) of the August 6, 2019 Lead Plaintiff deadline in the securities class action, Christie v. Cloudera, Inc. et al., No. 5:19-cv-03221, pending in the U.S. District Court for the Northern District of California.

If you purchased or otherwise acquired Cloudera securities between April 28, 2017 and June 5, 2019 (the “Class Period”) and suffered in excess of $50,000 in losses you may qualify to be a lead plaintiff – one who selects and oversees the attorneys prosecuting the case.

If you wish to serve as a lead plaintiff in this class action, you must move the Court no later than August 6, 2019. Contact Hagens Berman immediately for more information about the case and being a lead plaintiff:

https://www.hbsslaw.com/cases/CLDR

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing

CLDR@hbsslaw.com.

According to the complaint, Defendants misrepresented and concealed: (1) Cloudera’s ability to identify large enterprises interested in adopting the Company’s Hadoop-based platform; (2) that Cloudera needed to expend and increasing amount of capital on sales and marketing activities to generate new revenues, even as new revenue opportunities were diminishing; and (3) that Cloudera had materially diminished sales opportunities and prospects and could not generate annual positive cash flow.

“We’re focused on investors’ losses and the extent to which Defendants may have misled investors about the demand for its Hadoop-based platform,” said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Cloudera should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email CLDR@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 553237

SAN FRANCISCO, CA / ACCESSWIRE / July 30, 2019 / Hagens Berman Sobol Shapiro LLP updates investors in CannTrust Holdings Inc. (NYSE:CTST) and reminds them of the Lead Plaintiff deadline.

If you invested in CannTrust between November 14, 2018 and July 12, 2019 (the “Class Period”) and suffered losses you are included in the putative class of investors.

If you invested during the Class Period and suffered significant losses (in excess of $100,000), you may qualify to be a lead plaintiff – one who selects and oversees the attorneys prosecuting the case.

If you wish to serve as a lead plaintiff in this class action, you must move the Court no later than September 9, 2019 (the “Lead Plaintiff deadline”). Contact Hagens Berman immediately for more information about the case and being a lead plaintiff:

https://www.hbsslaw.com/hagens-berman-fraud-center/canntrust

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing

CTST@hbsslaw.com.

According to the complaint, Defendants concealed that (1) CannTrust was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending, (2) the greenhouse did not comply with certain regulations, and (3) it was reasonably likely that Health Canada would place an inventory hold until the Pelham facility becomes compliant with applicable regulations.

On July 25, 2019, the Company fired CEO Peter Aceto for cause and forced President & Chairman Eric Paul to resign.

“We’re focused on investors’ losses and whether Defendants misrepresented and concealed CannTrust’s compliance with applicable laws and regulations,” said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding CannTrust should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email CTST@hbsslaw.com.

# # #

About Hagens Berman

Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein
510-725-3000

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 554052

NEW YORK, NY / ACCESSWIRE / July 30, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Heron Therapeutics, Inc. (NASDAQ: HRTX)

Investors Affected : October 31, 2018 – April 30, 2019

A class action has commenced on behalf of certain shareholders in Heron Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (iii) as a result, Heron’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/heron-therapeutics-inc-loss-submission-form/?id=2685&from=1

Netflix, Inc. (NASDAQGS: NFLX)

Investors Affected : April 17, 2019 – July 17, 2019

A class action has commenced on behalf of certain shareholders in Netflix, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/netflix-inc-loss-submission-form/?id=2685&from=1

L Brands, Inc. (NYSE: LB)

Investors Affected : May 31, 2018 – November 19, 2018

A class action has commenced on behalf of certain shareholders in L Brands, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Victoria’s Secret and PINK businesses were having a material adverse effect on the Company’s cash flow, liquidity and debt levels; (b) Defendants lacked a reasonable basis for their positive statements about the ability of the Company to sustain its dividend; (c) the MD&A disclosures in filings L Brands made with the SEC were materially false and misleading; (d) the risk factor disclosures in filings L Brands made with the SEC were materially false and misleading; (e) the representations about L Brands’ disclosure controls in filings the Company made with the SEC were materially false and misleading; (f) the certifications issued by Defendants Wexner and Burgdoerfer on L Brands disclosure controls were materially false and misleading; and (g) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about L Brands’ then-current business operations and future financial
prospects.

Shareholders may find more information at https://securitiesclasslaw.com/securities/l-brands-inc-loss-submission-form/?id=2685&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 554055